Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess off-label use of loteprednol etabonate 0.25%
ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year
after Descemet membrane endothelial keratoplasty (DMEK). Topical corticosteroids have long
been the mainstay for preventing and treating cornea transplant rejection although none are
specifically approved for this purpose. The rates of immunologic rejection episodes and
steroid-induced ocular hypertension will be compared with the respective rates observed in
earlier studies with prednisolone acetate 1% suspension, loteprednol etabonate 0.5% gel, and
fluorometholone 0.1% suspension after DMEK.